TY - JOUR T1 - Clinical Impact of Panel Based Error Corrected Next Generation Sequencing versus Flow Cytometry to Detect Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML) JF - medRxiv DO - 10.1101/2020.08.23.20180372 SP - 2020.08.23.20180372 AU - Nikhil Patkar AU - Chinmayee Kakirde AU - Anam Fatima Shaikh AU - Rakhi Salve AU - Prasanna Bhanshe AU - Gaurav Chatterjee AU - Sweta Rajpal AU - Swapnali Joshi AU - Shruti Chaudhary AU - Rohan Kodgule AU - Sitaram Ghoghale AU - Nilesh Deshpande AU - Dhanalaxmi Shetty AU - Syed Hasan Khizer AU - Hasmukh Jain AU - Bhausaheb Bagal AU - Hari Menon AU - Navin Khattry AU - Manju Sengar AU - Prashant Tembhare AU - Papagudi Subramanian AU - Sumeet Gujral Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/28/2020.08.23.20180372.abstract N2 - We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission and evaluated MRD using sensitive error corrected next generation sequencing (NGS-MRD) and multiparameter flow cytometry (FCM-MRD) at the end of induction (PI) and consolidation (PC). Nearly 71% of patients harbored PI NGS-MRD and 40.9% harbored PC NGS-MRD (median VAF 0.76%). Patients harboring NGS-MRD had a significantly higher cumulative incidence of relapse (p=0.003), inferior overall survival (p=0.001) and relapse free survival (p<0.001) as compared to NGS-MRD negative patients. NGS-MRD was predictive of inferior outcome in intermediate cytogenetic risk and demonstrated potential in favorable cytogenetic risk AML. Patients who cleared PI NGS-MRD had a significantly improved survival as compared to patients who became negative subsequently indicating that kinetics of NGS-MRD clearance was of paramount importance. NGS-MRD identified over 80% of cases identified by flow cytometry at PI time point whereas FCM identified 49.3% identified by NGS. Only a fraction of cases were truly missed by NGS as compared to FCM-MRD. NGS-MRD emerged as the most important independent prognostic factor predictive of inferior outcome (p<0.001). We demonstrate a widely applicable, scalable NGS-MRD approach that is clinically informative and advantageous when compared to FCM-MRD in AML treated with conventional therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Wellcome Trust/DBT India Alliance Fellowship [grant number IA/CPHI/14/1/501485] awarded to Dr Nikhil PatkarAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IEC III (Project No 163)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAgreement to Share Publication-Related Data and Data Sharing Statement: Dr Nikhil Patkar, Haematopathology Laboratory, CCE Building, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Maharashtra, India, Pin: 410210. Email: nvpatkar{at}gmail.com; npatkar{at}actrec.gov.in. Phone: +91-22-27405000, Ext: 5773 ER -